Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
Charles B. Simone II, MD
Open to Accrual
Activation Date: March 26, 2020
To compare overall survival (OS) in patients with inoperable, early stage non-small cell lung cancer (NSCLC) randomized to stereotactic body radiation therapy (SBRT) with or without atezolizumab.
This is a joint SWOG & NRG Oncology FDA registration-intent trial. NRG Oncology institutions can credit NRG for their case accrual.
SWOG Study Chair: Megan E. Daly, M.D.
Patients must have histologically or cytologically proven Stage I-IIA or limited T3N0M0 non-small cell lung cancer (NSCLC) without radiographic evidence of nodal or distant involvement (N0M0). Patients may have T3 disease with the exclusion of multifocal tumors and pericardial involvement.
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.